Skip to main content

Table 6 Correlation between NLR/CD34 and clinicopathological features in prostate cancer

From: Correlation between peripheral blood neutrophil-lymphocyte ratio and CD34 expression in prostate cancer

Patients and tumor characteristics

NLR/CD34

Standard

Deviation

P-value

NLRLow/CD34Low

NLRLow/CD34High

NLRHigh/CD34Low

NLRHigh/CD34High

PSA level (ng/ml)

  < 10

8 (42.1)

1 (5.3)

5 (26.3)

5 (26.3)

0.169

0.011

 10 ~ 20

10 (34.5)

6 (20.7)

4 (13.8)

9 (31.0)

0.142

 

  > 20

3 (11.1)

4 (14.8)

6 (22.2)

14 (51.9)

0.050

 

Gleason score

  ≤ 6

6 (42.9)

3 (21.4)

3 (21.4)

2 (14.3)

0.227

0.005

 7

11 (39.3)

2 (7.1)

8 (28.6)

7 (25.0)

0.161

 

 8 ~ 10

4 (12.1)

6 (18.2)

4 (12.1)

19 (57.6)

0.059

 

T stage

 T1–2

15 (45.5)

4 (12.1)

7 (21.2)

7 (21.2)

0.196

0.018

 T3–4

6 (14.3)

7 (16.7)

8 (19.0)

21 (50.0)

0.084

 

Lymph node metastasis

 N0

18 (39.1)

8 (17.4)

11 (23.9)

9 (19.6)

0.201

0.011

 N1

3 (10.3)

3 (10.3)

4 (13.8)

19 (65.6)

0.173

 

Distant metastasis

 M0

16 (37.2)

9 (20.9)

7 (16.3)

11 (25.6)

0.282

0.029

 M1

5 (15.6)

2 (6.3)

8 (25.0)

17 (53.1)

0.186

 

TNM stage

 Stage II

19 (73.1)

2 (7.7)

2 (7.7)

3 (11.5)

0.195

0.000

 Stage III ~ IV

2 (4.1)

9 (18.4)

13 (26.5)

25 (51.0)

0.067

 
  1. NLR neutrophil-to-lymphocyte ratio, PSA prostate specific antigen